Ksilonex (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic receptor agonist. By binding to alpha‑1 receptors on the blood vessels of the nasal mucosa, it triggers vasoconstriction, which diminishes edema and opens the nasal airway. This localized action reduces the sensation of congestion without significant systemic effects.

The appropriate dose of Ksilonex is determined by the prescribing healthcare professional based on the patient’s age, condition, and response. Typical dosing instructions are provided on the product label, but the exact regimen should always follow the prescriber’s recommendation and local regulatory guidance.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Ksilonex.

To order Ksilonex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Ksilonex (Xylometazoline) and oxymetazoline belong to the same class of alpha‑adrenergic agonists. Both provide rapid relief of congestion, but Xylometazoline may have a slightly shorter duration of action, allowing more flexible dosing. Choice between them often depends on clinician preference, patient tolerance, and local formulary guidelines.

Ksilonex should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight. Ensure the container is tightly closed when not in use to maintain stability.

Ksilonex is applied intranasally. The recommended technique is to gently blow the nose, insert the nozzle into one nostril while keeping the other closed, and spray the prescribed number of sprays. Repeat in the opposite nostril if directed. Avoid sharing the device to prevent cross‑contamination.

Serious adverse events, although rare, include severe hypertension, nasal ulceration or bleeding, and systemic allergic reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience sudden high blood pressure, persistent nosebleeds, or signs of an allergic response.

Ksilonex should be avoided in children younger than 2 years unless a physician advises otherwise, in individuals with uncontrolled hypertension, severe cardiovascular disease, or those taking monoamine oxidase inhibitors. Patients with known hypersensitivity to Xylometazoline or any formulation component should also refrain from use.